Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Roswitha Forstpointner, Wolfgang Hiddemann, Michael Unterhalt et al.|Blood|2006Cited by 465
Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trialStefan Hagel, Hicham Chkirni, Alexander Brinkmann et al.|Intensive Care Medicine|2022Cited by 171